stockrow
Saturday 7 November 2026
Export HELP’s income statement to Excel — free account
Cybin Inc.
HELP Healthcare Biotechnology
- EPS
- +17.3%
- Free cash flow
- −25.6%
Quarter to June 2026, against a year earlier
8.96
0.57
+6.79%
Follow HELP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | — | — | — | — | — | — | — | 8 | 8 | 159 | +333.7% | |
| Gross margin, % | — | — | — | — | 23.15 | 0.00 | 0.00 | — | — | — | 0.00 | (23.2) pt | ||||||
| EBT | 0 | 0 | 0 | — | (24) | (54) | (36) | (58) | (82) | (148) | (171) | +126.2% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | — | (3,729.31) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | 0 | 0 | 0 | — | (24) | (54) | (36) | (58) | (82) | (148) | (171) | +126.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | — | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.01) | (0.02) | (0.01) | — | (9.51) | (12.17) | (7.22) | (7.22) | (4.02) | (4.25) | (4.24) | +102.3% | ||||||
| Cash flow | 0.00 | (0.02) | 0.00 | — | (5.48) | (8.20) | (7.36) | (6.16) | (3.58) | (3.83) | (2.69) | n/m | ||||||
| Capex | 0.00 | 0.00 | 0.00 | — | (0.07) | (0.09) | (0.51) | (0.06) | (0.07) | (0.04) | (0.03) | n/m | ||||||
| Free cash flow | 0.00 | (0.02) | 0.00 | — | (5.55) | (8.29) | (7.87) | (6.22) | (3.65) | (3.87) | (2.72) | n/m | ||||||
| Book value | 0.02 | 0.03 | 0.02 | — | 24.81 | 13.81 | 7.48 | 26.10 | 8.16 | 6.66 | 4.63 | +95.3% | ||||||
| Shares, m | 14 | 12 | 14 | — | 3 | 4 | 5 | 8 | 20 | 35 | 38 | +10.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | 87.26 | — | — | — | — | — | 1.94 | — | ||||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | (399.06) | — | — | — | — | — | (2.32) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | 0 | — | (14) | (36) | (36) | (51) | (72) | (133) | (141) | n/m | |||||
| Capex | 0 | 0 | 0 | — | 0 | 0 | (3) | (1) | (1) | (1) | (1) | +78.2% | ||||||
| Free cash flow | 0 | 0 | 0 | — | (15) | (36) | (38) | (52) | (74) | (135) | (142) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 0 | 0 | — | 47 | 40 | 13 | 155 | 101 | 165 | 175 | +109.5% | |||||
| Net debt | 0 | 0 | 0 | — | (49) | (43) | (13) | (155) | (94) | (157) | (166) | +98.7% | ||||||
| Shareholders’ equity | 0 | 0 | 0 | — | 65 | 61 | 36 | 216 | 165 | 232 | 242 | +116.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (27.85) | (49.89) | (22.78) | — | (69.65) | (78.84) | (66.63) | (43.74) | (40.42) | (68.67) | (72.78) | (40.8) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | — | (86.35) | (177.22) | (101.89) | (59.41) | (90.68) | (119.57) | (137.88) | (119.6) pt | ||||||
| ROE | (34.07) | (61.02) | (23.59) | — | (74.49) | (85.63) | (73.89) | (45.77) | (42.79) | (74.60) | (86.94) | (40.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 38 | 38 | 50 | 50 | 50 | 100 | — | +21.4% | |||||
| Revenue/emp, $m | — | — | — | — | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2021 · fundamentals updated 26 Oct 2026
Cybin Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics, Inc. | $626.6M | 9.0× | 9.2× | +44.86% (above 0%: growing) | n/m | +106.77% (above 0%: growing) | 95.25% | 30.67% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $621.5M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| DBVT DBV Technologies S.A. | $615.8M | — (loss-making) | — | −42.86% (below 0%: shrinking) | n/m | −64.93% (below 0%: shrinking) | 100.00% | (4,043.75%) | Compare |
| CADL Candel Therapeutics, Inc. | $615.2M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| HELP Cybin Inc. | $613.0M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | |
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $612.8M | — | — | +32.00% | — | −56.39% | 95.25% | 0.00% |